Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
This linear, covalently closed, double-stranded DNA offers a rapid, cell-free alternative to traditional plasmid DNA, addressing a critical bottleneck in nucleic acid therapeutics development
The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone
The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
At the center of the collapse is opposition from the Federal Trade Commission
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
Subscribe To Our Newsletter & Stay Updated
